A Rapid Reporting System for Third-Generation Cephalosporin-Resistant Bacteria in Blood Culture Tests at Our Hospital and Its Clinical Utility

Yuki NAGATA; Mikiyasu SAKAI; Hiroko KOMAI; Toshitaka WATARIGUCHI; Kouichi TANAKA; Yuri KIMURA; Osamu MATSUKUBO; Yui SUGIYAMA; Misaki MATSUMOTO; Rino ASAI; Atsushi KAWABATA

Return

A Rapid Reporting System for Third-Generation Cephalosporin-Resistant Bacteria in Blood Culture Tests at Our Hospital and Its Clinical Utility

VernacularTitle:当院の血液培養検査における第３世代セファロスポリン系薬耐性菌の迅速報告体制と臨床的有用性
Author: Yuki NAGATA ¹ ; Mikiyasu SAKAI ² ; Hiroko KOMAI ³ ; Toshitaka WATARIGUCHI ⁴ ; Kouichi TANAKA ¹ ; Yuri KIMURA ¹ ; Osamu MATSUKUBO ¹ ; Yui SUGIYAMA ¹ ; Misaki MATSUMOTO ¹ ; Rino ASAI ¹ ; Atsushi KAWABATA ⁵
Author Information

1. Depts. of Clinical Laboratory,　Toyota Kosei Hospital
2. Pharmacy, Toyota Kosei Hospital
3. Infection Control, Toyota Kosei Hospital
4. General Internal Medicine, Toyota Kosei Hospital
5. Infection Disease, Toyota Kosei Hospital
From:Journal of the Japanese Association of Rural Medicine 2024;72(5):367-373
CountryJapan
Language:Japanese
Abstract: Early detection of third-generation cephalosporin-resistant bacteria in blood culture tests influences the choice of antimicrobial agents. We report on our hospital’s system for early reporting of third-generation cephalosporin-resistant bacteria and its utility. The hospital operates a 24-h simple cefpodoxime (CPDX) testing system, where the content of a sample container with a positive blood culture result is smeared on a CA Sheep Blood Agar/VCM Chocolate EX II fractionation medium, and an antibiotic susceptibility test (AST) disk (Sensi-Disk CPDX) is placed at the center of the medium and incubated. The presence or absence of third-generation cephalosporin-resistant bacteria is estimated from the diameter of the growth inhibition zone. The physician in charge of AST makes comments on the chart based on the simple CPDX test results. The sensitivity of the simple CPDX test for detecting third-generation cephalosporin-resistant bacteria, based on AST results, was 95.5%. Among patients with failed antimicrobial therapy, the rate of switching antimicrobials before the AST results were known was 57.9% in cases where there were comments made by the physicians in charge of AST, compared with 42.9% in cases without comments. These results suggest that the simple CPDX test enables early and accurate detection of third-generation cephalosporin-resistant bacteria, facilitating early switching of antimicrobial agents through collaboration with physicians in charge of AST.